Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography

Dhananjeyan, Mugunthu R.; Liu, Jidong; Bykowski, Crystal; Trendel, Jill A.; Sarver, Jeffrey; Ando, Howard Y.; Erhardt, Paul

doi:10.1016/j.chroma.2006.10.038

Cited by 32 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recommendations for gemcitabine pharmacokinetic analysis, for which CDA regulates the catabolic route [10], specify that CDA blood activity must be inhibited to ensure a faithful analysis. Numerous analytical methods for measuring capecitabine metabolites in plasma have been reported [4,[11][12][13][14]. Among these latter, only one mentioned the use of a CDA inhibitor [14].…”

Section: Introductionmentioning

confidence: 99%

Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites

Besnard

Renée

Étienne-Grimaldi

et al. 2008

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites

Besnard

Renée

Étienne-Grimaldi

et al. 2008

Journal of Chromatography B

View full text Add to dashboard Cite

“…Recently, Guichard et al (2005) developed an HPLC-MS/MS method to quantify capecitabine, 5′-DFCR, 5′-DFUR and 5-FU, which was validated for mouse plasma, liver and human xenograft tumors, and cross-validated in human plasma and tumor. Dhananjeyan et al (2007) published an elegant method to determine capecitabine, 5′-DFCR, 5′-DFUR and 5-FU in mouse plasma, mouse serum and rabbit bile using HPLC-UV; however the lower limit of quantitation for this method was 1 μg/mL, which is not suffi cient for the clinical studies with capecitabine.…”

mentioning

confidence: 98%

A new, validated HPLC‐MS/MS method for the simultaneous determination of the anti‐cancer agent capecitabine and its metabolites: 5′‐deoxy‐5‐fluorocytidine, 5′‐deoxy‐5‐fluorouridine, 5‐fluorouracil and 5‐fluorodihydrouracil, in human plasma

Vainchtein

Rosing

Schellens

et al. 2009

Biomedical Chromatography

View full text Add to dashboard Cite

A rapid and selective liquid chromatography/tandem mass spectrometric method was developed for the simultaneous determination of capecitabine and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouracil (5'-DFUR), 5-fluorouracil (5-FU) and dihydro-5-fluorouracil (FUH(2)) in human plasma. A 200 microL human plasma aliquot was spiked with a mixture of internal standards fludarabine and 5-chlorouracil. A single-step protein precipitation method was employed using 10% (v/v) trichloroacetic acid in water to separate analytes from bio-matrices. Volumes of 20 microL of the supernatant were directly injected onto the HPLC system. Separation was achieved on a 30 x 2.1 mm Hypercarb (porous graphitic carbon) column using a gradient by mixing 10 mm ammonium acetate and acetonitrile-2-propanol-tetrahydrofuran (1 : 3 : 2.25, v/v/v). The detection was performed using a Finnigan TSQ Quantum Ultra equipped with the electrospray ion source operated in positive and negative mode. The assay quantifies a range from 10 to 1000 ng/mL for capecitabine, from 10 to 5000 ng/mL for 5'-DFCR and 5'-DFUR, and from 50 to 5000 ng/mL for 5-FU and FUH(2) using a plasma sample of 200 microL. Correlation coefficients (r(2)) of the calibration curves in human plasma were better than 0.99 for all compounds. At all concentration levels, deviations of measured concentrations from nominal concentration were between -4.41 and 3.65% with CV values less than 12.0% for capecitabine, between -7.00 and 6.59% with CV values less than 13.0 for 5'-DFUR, between -3.25 and 4.11% with CV values less than 9.34% for 5'-DFCR, between -5.54 and 5.91% with CV values less than 9.69% for 5-FU and between -4.26 and 6.86% with CV values less than 14.9% for FUH(2). The described method was successfully applied for the evaluation of the pharmacokinetic profile of capecitabine and its metabolites in plasma of treated cancer patients.

show abstract

“…We used the approach that is "based on the standard deviation (S.D.) of the response and the slope ( ) associated with the calibration curve" to calculate both LLOD and LLOQ [13,14] wherein LLOD = (S.D. × 3.3)/ ; and LLOQ = (S.D.…”

Section: Llod and Lloq Determinationsmentioning

confidence: 99%

Rapid and sensitive HPLC assay for simultaneous determination of procaine and para-aminobenzoic acid from human and rat liver tissue extracts

Dhananjeyan

Trendel

Bykowski

et al. 2008

Journal of Chromatography B

Self Cite

View full text Add to dashboard Cite

Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography

Cited by 32 publications

References 16 publications

Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites

Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites

A new, validated HPLC‐MS/MS method for the simultaneous determination of the anti‐cancer agent capecitabine and its metabolites: 5′‐deoxy‐5‐fluorocytidine, 5′‐deoxy‐5‐fluorouridine, 5‐fluorouracil and 5‐fluorodihydrouracil, in human plasma

Rapid and sensitive HPLC assay for simultaneous determination of procaine and para-aminobenzoic acid from human and rat liver tissue extracts

Contact Info

Product

Resources

About